GB2627344A — Cannabinoid based therapy

USPTO Abstract

Cannabinoid for use in prevention or treatment of a symptom of an autism spectrum disorder by preventing or reducing gastrointestinal inflammation, gastrointestinal hyperpermeability and/or colonic muscle thinning. The cannabinoid is administered to a subject who has or suspected of having gastrointestinal hyperpermeability, gastrointestinal inflammation, and/or colonic thinning. The symptom of autism may be a behavioural symptom and/or a gastrointestinal symptom. The subject may have been diagnosed with Crohn’s disease, coeliac disease, ulcerative colitis, type I diabetes, arthritis including spondylarthritis and psoriatic arthritis, or inflammation, particularly gastrointestinal inflammation. Also disclosed is a cannabinoid for use in the prevention, treatment, or reduction of gastrointestinal hyperpermeability or gastrointestinal inflammation. The cannabinoid may be cannabidiol (CBD), tetrahydrocannabinol (THC) or a combination thereof. The cannabinoid may be suitable for oral administration, e.g. in the form of a pharmaceutical or nutritional composition. The subject may be human and may be a child. Also disclosed is a dosage form of the cannabinoid comprising 0.1-20 mg/kg body weight of CBD and/or 0.05-6 mg/kg body weight of THC.